版本:
中国

BRIEF-Genmab announces new late stage combination study of Daratumumab in multiple myeloma

April 28 Genmab A/S:

* Genmab announces new phase III combination study of Daratumumab in multiple myeloma

* Study is expected to start in Q2 2017 and is designed to confirm results from MMY1001 study

* Prescription drug user fee act date of June 17, 2017 for Daratumumab

* Janssen Research with European myeloma network plans to start phase III study of Daratumumab in relapsed and refractory multiple myeloma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐